Sales & Marketing News | pharmaphorum

News

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

The FDA has started a priority review of Bristol Myers Squibb's Opdivo and Yervoy as first-line therapy for MSI-H/dMMR colorectal cancer.

News

FDA clears first therapy for rare disease CTX from Mirum

Mirum Pharma's Ctexli has become the first FDA-approved therapy for ultra-rare disease cerebrotendinous xanthomatosis (CTX).

News

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Pfizer has abandoned its haemophilia B treatment Beqvez in all world markets, saying weak demand made the business non-viable.

News

Compounders cast adrift after semaglutide shortage ends

The FDA has said there is no longer a shortage in the US market for Novo Nordisk's GLP-1 agonist semaglutide, ending sales of compounded forms.

News

Troubled gene therapy player bluebird sold for a song

At risk of defaulting on financial commitments, gene therapy firm bluebird bio has agreed to sell itself to private equity firms at a knockdown price.

News

NICE backs consolidation use of Blincyto in leukaemia

NICE backs NHS use of Amgen's Blincyto for the consolidation phase of treatment for some patients with acute lymphoblastic leukaemia.

FDA looks at Opdivo/Yervoy in first-line colorectal cancer

FDA clears first therapy for rare disease CTX from Mirum

Pfizer drops Beqvez, leaving its gene therapy cupboard bare

Compounders cast adrift after semaglutide shortage ends

Troubled gene therapy player bluebird sold for a song

NICE backs consolidation use of Blincyto in leukaemia

Ambrosia's sweet $100m round, and other biofinancings

Using AI-driven synthetic personas to take your insights fur...

News

Editor's Picks